Oncology Pharma Inc (ONPH) 股利

Oncology Pharma, Inc. engages in the development, manufacture and commercialization of therapeutics. The company is headquartered in San Francisco, California. The firm is focused on licensing, developing, manufacturing and commercializing therapeutics. The Company’s research, development, and commercialization of therapeutic drugs and medical devices designed for the treatment of many types of cancers. The firm offers a portfolio, such as Nanosmart Pharmaceuticals Inc. (Nanosmart Pharmaceuticals). The Company’s NanoSmart platform technology is a human-derived, antinuclear antibody (ANA) that targets areas of necrosis present in solid tumors. Its anti-cancer drugs in combination with medications, for treating a variety of cancers, such as breast, ovarian, lung, bladder, Kaposi's sarcoma, lymphoma and acute lymphocytic leukemia is doxorubicin. Its portfolio also includes Connect2Med, Sybleu, Inc. and Regen.